China Medical System Holdings (HKEX: 0867), headquartered in Hong Kong, has received clinical trial approval from China's National Medical Products Administration (NMPA) to study its selective TYK2 inhibitor CMS-D001 in ulcerative colitis (UC) and Crohn's disease (CD), adding two inflammatory bowel disease indications to a development programme that already spans psoriasis and atopic dermatitis.
CMS-D001 is an oral small molecule that selectively inhibits TYK2 (tyrosine kinase 2), a member of the JAK kinase family that sits upstream of inflammatory cytokine signalling pathways driven by IL-23, IL-12, and type I interferons. By targeting TYK2 specifically, the molecule is designed to suppress cytokine-mediated immune activation while minimising off-target activity on JAK1, JAK2, and JAK3 — the kinases implicated in the safety liabilities, including thrombosis and cardiovascular events, that carry black box warnings for pan-JAK inhibitors such as Pfizer's tofacitinib (Xeljanz).
The mechanistic rationale for a selective TYK2 inhibitor in IBD is grounded in the central role that IL-23 and IL-12 play in intestinal inflammation. Both cytokines signal through receptor complexes that require TYK2 activation, making TYK2 a logical intervention point in the pathological cascade underlying UC and CD. China Medical System said CMS-D001 exhibits enhanced precision in targeting these pathogenic mechanisms, and that its selectivity profile offers a differentiated safety proposition relative to broader JAK inhibitors currently used in clinical practice.
The proof-of-concept for selective TYK2 inhibition in an immune-mediated disease already exists in a related indication: Bristol Myers Squibb's deucravacitinib (Sotyktu) became the first FDA-approved TYK2 inhibitor when it received clearance for moderate-to-severe plaque psoriasis in 2022. Deucravacitinib operates through an allosteric mechanism targeting the regulatory domain of TYK2, and its approval validated the hypothesis that TYK2 selectivity can deliver clinical efficacy with a cleaner safety profile than pan-JAK inhibition. CMS-D001 will need to demonstrate comparable or superior outcomes in its own indications, including in the more competitive IBD landscape.
UC and CD are the two primary subtypes of inflammatory bowel disease, both characterised by chronic, relapsing inflammation of the gastrointestinal tract. UC predominantly affects the colonic mucosa, presenting with abdominal pain, diarrhoea, and mucopurulent bloody stools. CD can involve the entire digestive tract and is associated with intestinal fistula, obstruction, weight loss, and a high rate of disability. Both conditions impose a prolonged disease course that substantially diminishes quality of life.
In China, the patient population for these diseases is growing. According to a Frost & Sullivan report cited by the company, the number of UC patients in China rose from approximately 279,000 in 2015 to around 400,000 in 2019, and is projected to reach 918,000 by 2030. CD prevalence in China is estimated at 1.4 to 3.0 per 100,000 population, with an annual incidence of approximately 0.5 to 1.0 per 100,000, though underdiagnosis and misdiagnosis mean the true burden is likely higher.